Publication | Closed Access

Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: Is it necessary?

Pegylated Liposomal DoxorubicinLong-term UseCardiovascular DiseaseAtherosclerosisMyocardial InfarctionPharmacologyRoutine Cardiac SurveillancePharmacotherapyPublic HealthCardiovascular ToxicityMedicineCardiologyCardiovascular Imaging